Effect of IL-17 monoclonal antibody Secukinumab combined with IL-35 blockade of Notch signaling pathway on the invasive capability of hepatoma cells.

We investigated the effect of the IL-17 monoclonal antibody Secukinumab combined with IL-35 in the blockade of the Notch signaling pathway on the invasive capability of hepatoma cells. We examined the effects of IL-17 antibody or IL-35 treatment alone or in combination on cell invasion and migration capabilities with Transwell chambers. The mRNA levels of Hes1, Hes5, and Hey1 were tested using quantitative polymerase chain reaction. The protein expression of N1ICD, Snail, and E-cadherin protein expressions were measured with western blot. The expression of Hes1, Hes5, Hey1 and N1ICD were all very high in hepatoma cell lines, and were positively correlated with the invasive migration capabilities of the cells. The combination of IL-17 monoclonal antibody Secukinumab with IL-35 could effectively inhibit the Notch signaling pathway, as well as the invasive migration of the cells. Snail and E-cadherin are involved in the migration of hepatoma cells, and it has been established that Snail can regulate the expression of E-cadherin. IL-17 monoclonal antibody Secukinumab combined with IL-35 can increase E-cadherin and decrease Snail expression, which are positively correlated with cell invasive migration capabilities. Overall, treatment with both IL-17 antibody and IL-35 is more effective than each treatment alone. Notch signaling is activated in hepatoma cell lines and increases with the enhancement of cell invasive migration capabilities. IL-17 monoclonal antibody Secukinumab combined with IL-35 can block the Notch signaling pathway, simultaneously reducing the invasive migration capability of hepatoma cells.

[1]  O. G. Mouritsen,et al.  Influence of the active compounds of Perilla frutescens leaves on lipid membranes. , 2012, Journal of natural products.

[2]  M. Menon,et al.  Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase‐3 β/β‐catenin pathway , 2011, International journal of cancer.

[3]  P. Tak,et al.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.

[4]  W. Sung,et al.  Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. , 2010, Journal of hepatology.

[5]  Aleksandra M. Michalowska,et al.  Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. , 2008, Cancer research.

[6]  Yu Chen,et al.  Deregulated expression of Notch receptors in human hepatocellular carcinoma. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[7]  K. Boyd,et al.  The inhibitory cytokine IL-35 contributes to regulatory T-cell function , 2007, Nature.

[8]  I. McInnes,et al.  IL‐35 is a novel cytokine with therapeutic effects against collagen‐induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells , 2007, European journal of immunology.

[9]  Haiyang Xie,et al.  [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma]. , 2007, Zhonghua wai ke za zhi [Chinese journal of surgery].

[10]  Min Zhang,et al.  Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma. , 2006, Carcinogenesis.

[11]  J. Wands,et al.  Aspartyl‐asparagyl β hydroxylase over‐expression in human hepatoma is linked to activation of insulin‐like growth factor and notch signaling mechanisms , 2006, Hepatology.

[12]  Xuetao Cao,et al.  Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. , 2003, Cancer research.

[13]  H. Asakura,et al.  Gross appearance of hepatocellular carcinoma reflects E‐cadherin expression and risk of early recurrence after surgical treatment , 2003, Journal of gastroenterology and hepatology.

[14]  M. Buendia,et al.  Altered expression of E‐cadherin in hepatocellular carcinoma: Correlations with genetic alterations, β‐catenin expression, and clinical features , 2002, Hepatology.

[15]  T. Tanaka,et al.  Chemoprevention of azoxymethane-induced rat colon carcinogenesis by dietary capsaicin and rotenone. , 2001, International journal of oncology.

[16]  G. Berx,et al.  The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. , 2001, Molecular cell.

[17]  Francisco Portillo,et al.  The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression , 2000, Nature Cell Biology.

[18]  A. P. Soler,et al.  Expression of P-cadherin identifies prostate-specific-antigen-negative cells in epithelial tissues of male sexual accessory organs and in prostatic carcinomas. Implications for prostate cancer biology. , 1997, The American journal of pathology.

[19]  F. Podlaski,et al.  Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[21]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.